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ABSTRACT 
Purpose: A retrospective planning study comparing Volumetric Arc Therapy (VMAT) and 
Stereotactic Body Radiotherapy (SBRT) treatment plans for Non-Small Cell Lung Cancer 
(NSCLC). 
Methods and Materials: Five randomly selected early stage lung cancer patients were 
included in the study. For each patient, four plans were created: SBRT plan and three VMAT 
plans using different optimisation methodologies. A total of twenty different plans were 
evaluated. The dose parameters of dose conformity results, and target dose constraints results 
were compared for these plans.  
Results: The mean planning target volume (PTV) volume for all the plans (SBRT and 
VMAT) was 18.3cm
3
 with a range from 15.6cm
3
 to 20.1cm
3
.  The maximum dose tolerance 
to 1cc of all the plans was within 140% (84Gy) of the prescribed dose and 95% of the (PTV) 
of all the plans received 100% of the prescribed dose (60Gy). On all of the plans, 99% of the 
PTV received a dose greater than 90% of the prescribed dose and the mean dose on all the 
plans ranged from 67Gy to 72Gy. The planning target dose conformity for the SBRT and the 
VMAT (0
0
, 15
0
 collimator single arc plans and dual arc) plans showed the tightness of the 
prescription isodose conformity to the target.  
Conclusions: SBRT and VMAT are radiotherapy approaches which increase doses to small 
tumour targets without increasing doses to the organs at risk. Though VMAT offers an 
alternative to SBRT for NSCLC and the potential advantage of VMAT is the reduced 
treatment times over SBRT. The statistical results show that there was no significant 
difference between the SBRT and VMAT optimised plans in terms of dose conformity and 
organ at risk sparing.  
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INTRODUCTION 
Radiotherapy is the treatment of choice in cases of localised non-small cell lung cancer for 
which co-morbidities preclude surgery. After radical radiotherapy, local disease control and 
survival are limited [1-3]. Although increasing dose may improve local control, this may also 
be limited by the radiation-induced normal tissue toxicity.  Lungs are the main organs at risk 
structures (OAR) and any increase in dose may result in an increase of the V20 (percentage 
volume of healthy lung receiving at least 20Gy deduced from the volume of both lungs minus 
the Internal Target Volume, ITV) [1].  
The potential advantage of SBRT in the treatment of small tumours is the increased accuracy 
of delivery of higher biological effective doses, through better immobilisation and more 
precise delivery of multiple radiation beams [4]. SBRT has shown a promising progression in 
free survival rates without a significant increase in toxicity and no significant detrimental 
effect on lung function or quality of life in comparison with standard techniques [4]. The 
major limitations of SBRT are its complexity resulting from the multiple beams ranging from 
2 to 20, the image guidance procedures and the delivery of a large number of monitor units. 
The latter may be more time-intensive per fraction than conventional fractionated RT [4]. The 
longer treatment times mean that SBRT may be more affected by intrafraction tumour motion 
which increases with the duration of each treatment session. The long treatment times may 
not be well tolerated by patients since most lung cancer patients are either frail or elderly [4]. 
 
VMAT is a novel form of Intensity-Modulated Radiotherapy (IMRT) optimisation that 
allows a highly conformal treatment to be delivered in a single (or multiple) arc(s) [5]. It 
utilises at least 35 beam segments, using either a constant dose rate (cdr-VMAT) or variable 
dose rate (vdr-VMAT) during rotation [5]. VMAT offers an alternative to SBRT for NSCLC 
and the potential advantage of VMAT is the reduced treatment times over SBRT [5].VMAT 
allows the delivery of treatment with a continuously rotating gantry, simultaneous variation 
of dose rate, gantry speed and segment shape. 
 
The aim of the study was to compare SBRT and three different VMAT plans for small 
peripheral NSCLC tumours. The dose parameters of dose conformity results, and target dose 
constraints results were compared for these plans. 
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METHODS AND MATERIALS 
 
Patient Selection   
This is a retrospective study of 5 randomly selected early stage lung cancer patients. All the 
patients had peripheral lesions outside a 2cm radius of main airways and proximal bronchial 
tree 1A-1B (TNM 7
th 
edition), World Health Organisation (WHO) performance status 0-2. 
For each patient 5 plans were created: SBRT plan and 4 VMAT plans. Of the four generated 
plans for each patient (SBRT and three different VMAT plans), the differing variables for the 
VMAT plans included different collimator angles (0
°
 and 15
°
), single arc and dual arc plans.  
 
Target and Organs at Risk Definition 
The radiation oncologist outlined the internal target volume (ITV), which was the 
macroscopic disease visualised on the average 4D data set images. The ITV was expanded in 
all directions by a margin of 0.5cm to form the planning target volume (PTV). All the data 
sets were planned to the PTV on the time averaged data set CT images. The organs at risk 
(OARs) delineated included the oesophagus, the proximal bronchial tree, the trachea and the 
heart. The planner delineated the lungs and the spinal cord. All these organs at risk 
delineations were contoured as per national guidance produced by the ‘UK SBRT consortium 
based on the Radiation Therapy Oncology Group (RTOG)’ and ‘ROSEL’ protocols [6]. 
Based on these recommendations, a planning organ at risk volume (PRV)   was contoured for 
the spinal cord (SC) by adding a 0.5cm margin to evaluate the impact of organ motion. The 
spinal cord and oesophagus were contoured starting at least 10 cm above the PTV and to at 
least 10 cm below the inferior edge of the PTV. The heart was contoured as a single structure 
extending from the inferior aspect of the aortic arch to the apex of the heart inferiorly.  
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Treatment Planning 
All the plans used 6MV photons and the multi-leaf leaf collimators (MLCs) were conformed 
to the PTV with a 6mm margin to allow for penumbra. The main objective for each plan was 
that 95% of the PTV receives the prescription dose (60Gy), 99% of the PTV volume had to 
receive more than 90% of the prescription dose and that the maximum dose to 1cc of the PTV 
be less than 140% (84Gy) of the prescribed dose.  
 An enhanced collapsed cone algorithm, with full inhomogeneity correction based on 
individual pixel Hounsfield values and a 0.25cm dose calculation grid were used [7]. The 
DVH data for the PTV and organs at risk were used to determine the plan acceptability 
measured against the dose conformity requirements for the collapsed cone algorithm [7]. A 
VMAT plan was generated and optimised using ‘Autobeam’, following the same constraints 
as for the SBRT. The optimisation algorithm consisted of a fluence optimisation, followed by 
a classical segmentation and then direct aperture segmentation [8]. The final apertures were 
approximately conformal, using simple modulation to achieve homogeneity of the PTV dose, 
with the maximum allowable aperture extent equal to the PTV. The final dose distribution 
was achieved by iterative adjustments of relative beam weights. 
 
Target dose conformity  
The target dose conformity constraints used as dosimetric acceptance criteria for all the plans 
were the ratio of volume of tissue receiving the prescription dose V100% to the volume of the 
constructed PTV itself (VPTV): V100%/VPTV). The conformity index was given as the ratio of 
volume of tissue receiving the prescription dose V100%, to the volume of the constructed PTV 
itself, VPTV (V100%/VPTV). The closer to 1 the conformity index was, the more conformal the 
plan, and if less than one the less conformal it was.  
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Dose Volume Constraints 
Normal tissue goals (lungs, spinal cord, oesophagus, brachial plexus, heart and the proximal 
bronchial tree) were based on the departmental dose tolerances as shown on table 1. The 
percentage volume of healthy lung receiving 15Gy, 10Gy and 5Gy was also set to calculate 
the volume of lung being radiated. This emanated from the assumption that VMAT was 
spreading dose around since the whole arc was spreading the dose around the patient. The 
mean lung dose (MLD) was also calculated and used for predicting lung toxicity. The 
oesophageal surface area receiving at least 55Gy and the oesophageal volume receiving at 
least 60Gy were the most statistically significant predictive factors for early oesophagitis  in a 
study of lung carcinoma radiotherapy[9].The dose tolerance to 1cc of the oesophagus was 
less than 27Gy with a minor deviation of between 27 and 28.5Gy. The tolerance for 1cc of 
the heart was set at less than 27Gy, with an acceptable minor deviation of between 27 and 
29Gy.For those tumours situated in the apex of the heart, the dose tolerance to 1cc of the 
brachial plexus was set less than 27Gy. The trachea and the bronchial tree were the other 
organs at risk that were recorded and compared for this study. 
 
Statistical analysis 
The one-way analysis of variance (ANOVA) was used to determine whether there are any 
significant differences in the target conformity indices between  SBRT, VMAT 0
°
, VMAT 
15
°
  and Dual Arc plans. The statistical data included the mean and standard deviations 
derived using three different post-hoc tests; the least significant difference (LSD) test, 
Bonferroni post hoc analysis and Dunnet analysis [10]. The significance of the difference 
between the target conformity indices was indicated by a p-value. The differences were 
considered significant when p <0.05. 
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RESULTS 
Target dose constraints 
Table 2 shows the volume of PTV receiving 100% of dose for patient 1 to patient 5 for the 
SBRT and the other 3 different VMAT plans and the dose conformity indices for the different 
plans. Table 3 shows the volume of tissue receiving 50% of the dose and this is a 
representation of the gradient index. The value of the gradient index is greater than unity in 
all patients. A value that is closer to unity represents a faster dose fall off in normal tissue and 
may imply lower dose to the OARs. 
 
As shown in figure 1, VMAT0
°
 and the VMAT15
°
 plans had better conformity. The 
VMAT15
°
 plans never drifted further away from the perfect value than the other plans. All 
the plans for patient no.1 were near the perfect value, whereas the SBRT plan for patient no.2 
drifted the furthest, followed by the dual arc plan for patient no.3. Overall, the graphical data 
shows that the VMAT15
°
 had an average closer to the near perfect plan. 
 
Table 4 shows the DVH indices for patient 1-5. The table shows the minimum doses 
delivered to 1cc for each plan for every patient. This table also showcases the dose to 99% 
and 95% of the target. As per the departmental protocol 95% of the target was expected to 
receive the prescription dose, a parameter which all the plans for the patients met. The 
average dose for the four plans for patient no.1 was 60.3Gy. It also shows the maximum dose 
to 1cc of the target volume for patient no.1. The mean value of the maximum dose for the 
plans for patient no.1 was 82.39Gy. VMAT plans had higher doses than SBRT plans for all 
the patients. The mean dose for the target volume for all the patients was also noted for their 
different plans.  
 
Figure 2 shows the gradient index for all the plans for the five patients as shown in table 3. 
Most of the dual arc plans and all of the VMAT15
° plans were closer to a unit than most plans 
which meant a faster dose fall off for these plans. The difference of the plans for the 5 
different patients is marginal as can be seen on the figure 1 and 2. 
 
Two of plans had the PTV close to the chest wall and the other three were in the lung further 
from the chest wall.  The mean PTV volume for all the plans (SBRT and VMAT) was 
18.3cm
3
 with a range from 15.6cm
3
 to 20.1cm
3
.  As shown in table 4, the maximum dose 
tolerance to 1cc of all the plans was within 140% (84Gy) of the prescribed dose and 95% of 
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the PTV of all the plans received 100% of the prescribed dose (60Gy). On all of the plans, 
99% of the PTV received a dose greater than 90% of the prescribed dose and the mean dose 
on all the plans ranged from 67Gy to 72Gy. 
 
Planning Target Volume Dose Conformity 
Table 2 shows that there was not much difference in the dose conformity for the SBRT and 
VMAT plan.  The values for the conformity index ranged from 1.03-1.2. The volume of 
tissue receiving 50% of the prescription dose, V50%, was used as a dosimetric measure of the 
dose fall-off outside the target volume (table 3). When expressed as a ratio to the volume of 
the PTV, it ranged from 4.6 to 6.12. This meant that the dose fall-off from the PTV varied for 
both plans but there was no significant difference between the SBRT and the VMAT plans. 
The statistical outcome of the target conformity values shows that the p-values for all the 
plans were close to unity and VMAT 15
° and VMAT 0° being the closest. With the 
Bonferroni post-hoc analysis, the p-value was unity for all plan comparisons. The Least 
significant difference (LSD) test had lower p-values. For instance, the SBRT comparison 
with   VMAT 0
° 
and VMAT 15
°  
the p-values were 0.360 and 0.431 respectively.  
Organ at Risk Doses 
The lung V20, defined as the percentage volume of both lungs minus the ITV receiving at 
least 20Gy (table1). In this study, we used the ITV as defined on the free breathing 
localisation computed tomography scan to determine V20. The V20 had a mean value of 5.9% 
for a total of 5 patients. The patient with the smallest tumour had a V20 value of 7.0%, which 
represented a minor protocol deviation. The percentage volume of lung receiving 15Gy (V15), 
the percentage volume of the lung receiving 10Gy (V10) and volume receiving 5Gy (V5) were 
all calculated. The mean lung dose (MLD) ranged from 2.6 to 6.4 Gy, with a mean value of 
4.6Gy. This dosimetric parameter is calculated from the dose volume histogram statistics for 
the combined left and right lung volumes. The tolerance for the spinal cord and spinal cord 
PRV were considered. The spinal cord PRV had a maximum tolerance of less than 25Gy. The 
average dose to the spinal cord +0.5cm margin was 6.885Gy and on average 1cc of the spinal 
cord +0.5cm got 3Gy. The mean dose to 1cc of the oesophagus for the 5 patients was 
9.665Gy. The doses to 1cc of the brachial plexus, 1cc of the heart, 1cc of the trachea, and 1cc 
of the bronchial tree were also recorded. 
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DISCUSSION 
This study showed that both SBRT and VMAT techniques achieved high dose conformity 
treatment plans. Published studies for SBRT report promising progression-free survival rates 
with less significant increase in toxicity compared with standard techniques [4].  This could 
be explained by the fact that in SBRT plans the tumour dose is increased significantly whilst 
maintaining high dose conformity as indicated in this study. A reviewed report approximated 
a 2-year actual survival of 89%, a 2-year local progression-free survival of 65% and 
incidence of grade ≥2 pneumonitis of 6.5% [4]. This compares favourably with reported 2-
year survival of 53% and incidence of grade 2 late radiation pneumonitis of 1.9-18% and 
grade ≥ 3 pneumonitis of 6% for conventional radiotherapy for stage I disease [4].  
 
The DVH values for SBRT and VMAT plans showed no significant difference in the 
percentage volume of healthy lung receiving 20Gy and the mean lung dose. Hence, this study 
did not pursue the idea of comparing the doses received to the OARs. The amount of dose 
deposited to the healthy tissue could also be taken from the rapid dose fall off provided by 
SBRT and VMAT. The Conformity (50%):a Volume (body 50%) / volume PTV in Table 3 
showed that these different plans provided a significant dose fall off from the target which 
meant a reduction to V20 and the mean lung doses. The results from this study about the 
rapid fall off of dose from the target allayed all the concerns that had arisen at the beginning 
of this study about VMAT increasing the chances of radiation pneumonitis because it spread 
the dose around the patient in both lungs [11]. Toxicity is not expected to be a hindrance to 
using VMAT and will profit from the shorter delivery time with VMAT compared to SBRT 
[11]. 
In the SBRT plans, it was recommended that wherever possible no entrance beam would pass 
through the spinal cord and the same recommendation was used for VMAT, no arcs were 
allowed to pass through the spinal cord. This allowed dose to this structure to be minimised 
in case of any future treatments for the patient. In the SBRT plans this was done by just 
deleting the beams that passed through the structure and in the VMAT plan it was done by 
just selecting the arc angles that avoided the structure. In the SBRT plans it was also 
important to avoid the beams directions from being directly opposed as this would have 
compromised on the dose conformity.  
Since the intended dose to the PTV volume was 60Gy, increasing the minimum DVH dose 
constraint to the PTV was a good way of helping achieve better coverage. The percentage 
volume can also be lowered if coverage is achieved easily but the OAR doses are being 
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compromised. If the tumour volume is very small, the relative size of the MLCs may reduce 
the ability to conform closely to the tumour. This can lead to a more baggy 100% isodose 
line, which would be unavoidable. After optimisation of the SBRT plans, each of the 
segments was checked for shape irregularity. All the segments were expected to conform to 
the shape of the PTV with minimum modulation. If any of the segments had individual MLCs 
protruding towards the isocenter this would have been caused by the maximum dose 
objectivity. The PTV maximum objective would have to be reduced or remove the segment 
and re-optimise the plan to improve this.  On the VMAT plans, the jaws and the MLCs could 
not be adjusted after the plan had been optimised, so for this reason the only way of adjusting 
the dose coverage or the tolerances to the OAR was to adjust the objective values and re-
optimise the VMAT plans. This contributed to a considerably increased planning time. 
Introducing a 15
°
   collimator twist helped to counter for this problem by removing the 95% 
(57Gy) isodose on the slice just after the PTV in some plans. The 15
°
  VMAT plan had better 
coverage than the 0
°
 plan especially in cases where the PTV was embedded within the lung. 
This is because introducing a 15
°
   collimator twist angle removed the extra 57Gy isodose on 
the slice just after the PTV margin. On some of the plans that had the PTV attached to the 
chest wall the 15
°
 collimator twist did not manage to get rid of the extra 95% outside the 
PTV.   
When using the VMAT technique, the single arc VMAT managed to achieve the required 
target coverage and homogeneity in all cases, managing to keep the OAR dose tolerances. 
Adding a second arc did not improve plan quality considerably and at times led to similar 
results to the single arc. Target goal doses were achieved and OAR tolerance doses respected 
in all cases. This meant that there was no need to use dual arc VMAT, which instead would 
have increased the treatment time and probably increased the skin doses. There was no real 
benefit of using dual arc VMAT over single arc VMAT. 
This study was based on the use of 4D-CT lung scans. Therefore, the expansions used for the 
ITV to CTV and then to PTV margins were small. The use of these scans resulted in lesser 
expansion margins which in the end meant fewer doses to the PTV + 2cm margin and this 
reduced dose to the surrounding healthy tissue. Several studies have shown that using four-
dimensional computed tomography for treatment planning results in a smaller PTV for most 
tumours than fast computed tomography with a standard motion margin applied [12]. 
Treating in breath-hold or with gating, previously constrained by the length of every 
treatment session, could now be tried with the use of VMAT [13].  
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Although the isodose coverage between VMAT and SBRT is similar, VMAT can be 
delivered in a shorter time even without taking into account the time taken during setup in the  
protracted treatment [14]. The small dosimetric differences between the SBRT and VMAT 
plans are unlikely to be clinically relevant. Shorter treatment sessions make for a more 
comfortable experience for the patient with reduced risk of changes in patient positions and 
intrafraction tumour and organ position variation and allow for greater departmental 
efficiency [14]. Some studies showed that Volumetric modulated arc therapy reduced the 
treatment time of SBRT plans by 37% and improved isodose conformity [14]. Conformal and 
VMAT techniques for lung SBRT had similar dosimetric quality but VMAT had improved 
target coverage and took 59% less time to deliver, although monitor units were increased by 
5% [14]. 
The main challenge with VMAT is that the dosimetric and calculation time is currently 
greater than that for the SBRT, as the former involves longer optimisation times on Pinnacle 
treatment planning system. The dosimetric time should, however, decrease when this is an 
integrated process within Pinnacle. The other disadvantage of VMAT is the inability to adjust 
the jaws and MLCs after optimisations which mean the plan has to be re-optimised all the 
time and adjustment needs to be done. This also contributes to the increased planning time for 
VMAT plans. 
 
 
Limitations  
The major limitation encountered in the study was that there were not many SBRT patients 
and hence this study had a small population of patients. 
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CONCLUSION 
SBRT and VMAT are radiotherapy approaches which increase doses to small tumour targets 
without increasing doses to the organs at risk. Though VMAT offers an alternative to SBRT 
for NSCLC and the potential advantage of VMAT is the reduced treatment times over SBRT. 
The statistical results show that there was no significant difference between the SBRT and 
VMAT optimised plans in terms of dose conformity and organ at risk sparing. 
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Table 1. Organs at risk dose constraints used in plan optimisations. 
 
Structure   Conditions   Tolerance   Minor deviations 
 
 
Lung ITV    V(PTV) ˂ 20cc  V20 ˂ 5.0%  5.0-8.0% 
 
V(PTV) 20-40cc    V20 ˂ 6.0%     6.0-10.0% 
 
V(PTV) ˃40cc  V20 ˂ 10%  10.0-15.0% 
 
 
Spinal cord+0.5cm   Max ˂ 25Gy  25-28Gy 
 
Oesophagus   1cc ˂27Gy  1cc ˂ 27Gy  27-29Gy 
 
 
Brachial Plexus  1cc ˂ 27Gy  27-29Gy 
 
Heart    
5# schedule   1cc ˂ 27Gy  27-29Gy 
8# schedule  1cc ˂ 50Gy  50-60Gy 
 
 
 
Trachea    1cc˂32Gy  32-35Gy 
 
Proximal    1cc˂32Gy  32-35Gy 
bronchial tree 
 
Abbreviations; OAR; Organ at risk, PTV; planning target volume  
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Table 2. Dose conformity indices for the SBRT and the VMAT plans computed based on 
100% conformity, 100% body volume and 100% PTV.  
 
Patient   SBRT           VMAT (0° CT)              VMAT (15
° CT)        Dual Arc
 
 
1.  1.04  1.03   1.04  1.05 
 
2.   1.2  1.07   1.1  1.1 
  
3.  1.08  1.1   1.11  1.18 
 
4.  1.09  1.1   1.09  1.13 
 
5.  1.16  1.13   1.11  1.09 
 
 
 
 
Abbreviations; SBRT; stereotactic body radiation therapy, VMAT; volumetric modulated 
arch therapy,  CT; collimator twist, PTV; planning target volume 
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Table 3. Dose conformity indices for the SBRT and the VMAT plans computed 50% 
conformity, 50% body volume and 50% PTV. 
 
Patient   SBRT           VMAT (0° CT)           VMAT (15
° CT)        Dual Arc
 
 
1.  4.6  4.72   5  5 
 
 
2.  6.4  5.1   5.2      5.2 
  
3.  5  5.5   5.88  5.09 
 
4.  6.12  5.37   5.28  5.11 
 
5.  5  5.44   4.99  5.86 
 
 
 
 
Abbreviations; SBRT; stereotactic body radiation therapy, VMAT; volumetric modulated 
arch therapy,  CT; collimator twist, PTV; planning target volume 
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Table 4: The DVH indices showing the PTV doses for each computed SBRT and VMAT 
plan.  
 
 
 
 
 
PTV volume 
20.1cm3 
 
 
 
Minimum dose to 
1cc of the PTV 
(Gy) 
 
Maximum 
dose to 1cc 
of the PTV 
(Gy) 
 
Mean dose 
 
 
  
 
 
PTV99% 
 
PTV95% 
 
P
atien
t 1
 
   
 SBRT 60.01 81.00 71.73 57.27 60.00 
VMAT(OO 
collimator twist) 
60.58 82.76 70.50 57.99 60.00 
VMAT(150 
collimator twist) 
60.07 83.35 71.79 57.47 60.00 
Dual Arc 60.53 82.43 70.50 58.14 60.00 
 
 
 
PTV volume 
15.6cm3 
 
 
 
SBRT 60.63 80.22 69.99 57.61 60.00  
P
atien
t 2
 
VMAT(OO 
collimator twist) 
59.59 82.07 70.00 56.07 60.00 
VMAT(150 
collimator twist) 
60.35 83.36 71.00 56.78 60.00 
Dual Arc 59.81 81.51 70.00 56.31 60.00 
 
 
 
PTV volume 
17.9cm3 
 
 
SBRT 60.43 77.40 67.99 58.50 60.00 
 
P
atien
t 3
 
VMAT(OO 
collimator twist) 
60.85 79.76 70.65 57.89 60.00 
VMAT(150 
collimator twist) 
60.94 80.21 71.01 58.73 60.00 
Dual Arc 60.48 79.23 69.99 58.88 60.00 
 
 
 
PTV volume 
 
19.2cm3 
SBRT 60.66 83.78 71.97 58.38 60.00 
 
P
atien
t 4
 
VMAT(OO 
collimator twist) 
60.18 82.22 71.57 57.99 60.00 
VMAT(150 
collimator twist) 
59.49 82.98 71.66 58.07 60.00 
Dual Arc 60.09 83.33 70.99 58.16 60.00 
 
 
 
PTV volume 
18.8cm3 
 
 
SBRT 60.99 82.99 71.91 58.90 60.00 
 
P
atien
t 5
 
VMAT(OO 
collimator twist) 
60.09 83.00 71.88 58.63 60.00 
VMAT(150 
collimator twist) 
60.48 81.22 71.09 58.90 60.00 
Dual Arc 
 
59.99 82.29 71.19 58.47 60.00 
Abbreviations; SBRT; stereotactic body radiation therapy, VMAT; volumetric modulated 
arch therapy, PTV; planning target volume 
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Figure1. Conformity Indices for the SBRT and the VMAT plans  
SBRT
VMAT(0 collimator
twist)
VMAT(15
collimator twist)
Dual Arc
patient no.  
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Figure2. Conformity Indices for the SBRT and the VMAT plans  
SBRT
VMAT(0
collimator twist)
VMAT(15
collimator twist)
Dual Arc
patient no.  
